Analyst Ratings For Intercept Pharmaceuticals
Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter:
Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $25
Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $30 to $25.
SVB Leerink Maintains Market Perform on Intercept Pharmaceuticals, Lowers Price Target to $27
SVB Leerink analyst Thomas Smith maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Market Perform and lowers the price target from $30 to $27.
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell
• SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million.
B. Riley Securities Upgrades Intercept Pharmaceuticals to Buy, Raises Price Target to $30
B. Riley Securities analyst Mayank Mamtani upgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Neutral to Buy and raises the price target from $25 to $30.
Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has announced results from a new analysis examining obeticholic acid’s (OCA) potential to improve transplant-free survival in…
Intercept Announces New Long-Term Data Demonstrating Potential Of Obeticholic Acid To Improve Transplant-Free Survival In Patients With PBC
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced results